• “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置时时彩网络平台>技术资料首页>行业动态>公司动态>Covidien斥资2.5亿美元收购Somanetics 拓展具有市场领先技术的监护平台

    江苏快3大小单双玩法技巧: Covidien斥资2.5亿美元收购Somanetics 拓展具有市场领先技术的监护平台

    Covidien2010年6月18日 14:49 点击:3132

    美国Covidien

    Covidien宣布签署收购Somanetics Corporation的最终协议

    • 拓展具有市场领先技术的监护平台
    • 对现有销售基础架构进行补充;地域扩张机会
    • 强大的临床研究产品组合

    时时彩网络平台 www.qlgr.net 都柏林和密歇根州Troy--(BUSINESS WIRE)--(美国商业资讯)--Covidien plc(纽约证券交易所代码:COV)和Somanetics Corporation(纳斯达克代码:SMTS)今天宣布,双方已经签署了一项最终合并协议,Covidien将以每股25.00美元(现金)的价格收购Somanetics Corporation所有在外流通股,总价值为2.50亿美元,以净现金支付。此次收购符合Covidien的战略——拓展至相邻地区,并且对该公司能够建立全球竞争优势的产品类别进行投资。

    Somanetics是大脑和身体血氧测量领域的领导者。该公司2009年的销售额为5000万美元,拥有大约150名员工。其INVOS®(体内光谱学)大脑/身体血氧计是一种无创患者监护仪,能够对存在血流量受限风险的患者的大脑和身体中的血氧水平进行持续测量,从而使临床医生能够检测和纠正多种危险的并发症。INVOS系统是经证明能够改善患者结果的唯一已经商业化的大脑/身体血氧计。

    Covidien呼吸和监护解决方案部门总裁Pete Wehrly说:“对Somanetics的收购将使Covidien能够扩大产品组合,并且增添又一种市场领先的监护技术。我们目前在欧洲进行分销的Somanetics产品系列将会拓展我们在手术室领域的业务范围。此次收购将帮助我们实现提高生命质量和改善患者结果的使命。”

    Somanetics总裁兼首席执行官Bruce Barrett说“我们十分高兴能够加入Covidien,并使Somanetics的股东实现更大的投资价值。Covidien是我们的INVOS系统在欧洲的独家分销合作伙伴,我们与该公司拥有长期稳固的合作关系。我们的专有技术是Covidien呼吸和监护产品的理想补充。”

    财务摘要

    根据该协议,Covidien将以每股Somanetics股票25.00美元(现金)的价格支付总计大约2.50亿美元,以净现金支付。与Somanetics的结合将可以拓展Covidien的产品组合,并且预计将对营收和收益增长率都能够产生促进作用。

    此次交易将采用由Covidien的全资子公司实施全现金要约收购的形式,随后是第二步合并。该交易还有待于惯例成交条件的达成,包括收到某些监管许可,预计该交易将于2010年7月31日之前完成。两家公司的董事会都已经一致批准了该交易。Somanetics的所有董事和高管都已经确定了他们出售其所持全部股票的意向。一旦该交易完成,Covidien将在财务报告中把Somanetics业务作为其医疗器械业务部门血氧测量和监护产品系列的一部分。

    假设交易于2010年7月31日完成,按照一般公认会计原则(GAAP)衡量,Covidien预计该交易将会稀释2010年和2011年的每股收益。按照非GAAP计算,不计交易、重组和其他成本,Covidien预计该交易将不会对2010财年每股收益产生影响,并且会推动2011财年每股收益略微增长。

    关于Covidien

    Covidien是一家全球领先的健康保健产品公司,致力于为改善患者的用药效果提供创新的医疗解决方案,并通过在临床领域的领导地位及卓越表现创造价值。Covidien在三大业务领域制造和销售业界领先的产品线,并提供相应服务,这三大领域包括:医疗设备、医药产品和医疗用品。2009年,Covidien公司的营业收入高达107亿美元,公司在全球60多个国家拥有42,000多名员工,其产品销往140多个国家。更多有关我们业务的信息,请登录公司网站:www.covidien.com。

    关于Somanetics

    Somanetics Corporation开发、生产和销售INVOS®大脑/身体血氧计。INVOS是经证明对2.5公斤以上患者进行手术后能够改善结果的唯一已经商业化的大脑/身体血氧计。INVOS系统是大脑/身体血氧测量的临床参考标准,拥有12年的市场记录和750多项临床参考,并且在大约800家美国医院进行了部署。Somanetics开发、生产和销售Vital Sync™系统,这种设备将来自床边设备的数据整合进一个单独系统中,以实现更好的患者评估和决策、数据管理以及数据存储。Somanetics通过直接的美国销售团队和临床教育团队为客户提供支持。Covidien在欧洲、加拿大、中东和南非销售INVOS系统,Edwards Lifesciences作为代理在日本销售INVOS系统产品。垂询详情,请访问://www.somanetics.com/。

    前瞻性陈述

    本新闻稿包含非历史事实的前瞻性陈述。Covidien和Somanetics已经通过“相信”、“也许”、“能够”、“会”、“或许”、“可能”、“将”、“应该”、“预计”、“打算”、“计划”、“期望”或者“继续”等词语、这些词语的反义词、其他类似术语或者未来日期的使用,识别了一些这类前瞻性陈述。本新闻稿的前瞻性声明包括但不限于:有关交易预计完成时间以及交易对Covidien的业务和竞争地位产生的影响的声明;有关未来创新和市场增长的声明;以及有关Covidien的未来财务业绩和财务状况的声明。提醒投资者和证券持有者不要过分依赖这些前瞻性陈述。由于众多风险和不确定性,实际结果可能会与当前预期产生实质性差异??傻贾率导式峁朐て诓钜斓姆缦蘸筒蝗范ㄐ园ǎ航灰淄瓿墒奔涞牟蝗范ㄐ?;Somanetics有多少股东将在此次要约中出售其股票的不确定性;出现具有竞争力的要约的风险;该交易各种成交条件可能无法达成或者免除的可能性,包括政府机构可能阻止、推迟或者拒绝为交易完成授予许可;交易中断的影响,使其更难维持与员工、客户、厂商和其他业务合作伙伴的关系;与股东有关该交易的诉讼可能导致重大的辩护、补偿和债务成本相关的风险;其他业务影响,包括非Covidien和Somanetics所能控制的行业、经济或政治条件的影响;交易成本;实际或者或有负债;以及Covidien和Somanetics向美国证券交易委员会(U.S. Securities and Exchange Commission)提交的文件中所讨论的其他风险和不确定性,包括Covidien和Somanetics最近的10-K表年度报告和随后的10-Q表季度报告中的“风险因素”部分, Covidien旗下全资子公司Covidien DE Corp.将要提交的要约收购文件,以及Somanetics将要提交的邀请和建议声明。除非法律要求,否则Covidien和 Somanetics都不会承担任何义务来更新任何前瞻性陈述,以反映新信息、未来发展或者其他情况。这项公告中的所有前瞻性陈述都完全受到该警戒性声明的限制。

    非GAAP财务信息

    本新闻稿中包含一种非GAAP财务指标,这种非GAAP财务指标用于衡量Covidien的业绩,应当被视为Covidien按照GAAP衡量的财务业绩指标的补充或者更高级指标,而不是替代者。Covidien的非GAAP指标的定义可能与其他公司采用的类似名称财务指标的定义存在差异,因此,在理解Covidien如何定义其非GAAP财务指标时应特别注意。

    尤其是,预计的每股收益稀释不包含交易、重组和其他成本的任何一次性费用。

    Covidien管理层之所以使用这种非GAAP财务指标,是因为认为它对于评估不计交易相关费用的每股收益稀释而言有用且更具意义。Covidien管理层还使用该非GAAP财务指标来进行财务及经营方面的决策,因为管理层认为它以支持具有重要意义的不同期间对比的方式反映了Covidien的当前业务的基本经济状况。这类对比或许更具有意义,这是因为根据GAAP衡量的经营业绩可能包括:有时与理解Covidien业务不一定相关以及某些情况下难以准确预测未来期间的事项。Covidien管理层认为,这种非GAAP财务指标为投资者和其他人提供了有用信息,可帮助他们以与管理层相同的方式(如果他们选择这样)来理解和评估Covidien的当前经营业绩和未来前景。但是,非GAAP财务指标拥有限制,因为它们没有包含可影响Covidien运营的所有收益和费用事项。Covidien管理层通过同时按照GAAP衡量公司业绩,来对此以及其他限制进行弥补。

    有关要约收购的重要信息

    本新闻稿既不是购买Somanetics任何证券的要约,也不是出售Somanetics任何证券的要约邀请。Covidien旗下的间接全资子公司Covidien DE Corp.(“买方”)还没有针对本新闻稿中所述的Somanetics普通股实施要约收购。

    一旦实施要约收购,买方将以Schedule TO形式向美国证券交易委员会提交要约收购声明和相关证明文件,包括收购要约、转送函和其他相关文件。在实施要约收购之后,Somanetics将以Schedule 14D-9形式向美国证券交易委员会提交一份要约收购邀请和建议声明。这些文件将包含有关Covidien、Somanetics、该交易和其他相关事务的重要信息。当这些文件公布时,投资者和证券持有者需要仔细阅读每份文件。

    投资者和证券持有者将可以通过访问美国证券交易委员会网站www.sec.gov,来免费获得要约收购声明、要约收购邀请和建议声明以及买方和Somanetics向美国证券交易委员会提交的其他文件的副本。此外,投资者和证券持有者还可以通过以下联系方式来免费获得这些文件的副本:

    免责声明:本公告之原文版本乃官方授权版本。译文仅供方便了解之用,烦请参照原文,原文版本乃唯一具法律效力之版本。

    Covidien

    投资者关系部

    508-452-4650

    [email protected]

    Somanetics Corporation

    投资者关系部

    248-244-1409

    [email protected]

     

    Contacts

    Covidien
    Eric Kraus, 508-261-8305
    企业传播部高级副总裁
    [email protected]

    Coleman Lannum, CFA, 508-452-4343
    投资者关系部副总裁
    [email protected]

    Bruce Farmer, 508-452-4372
    公关部副总裁
    [email protected]

    Brian Nameth, 508-452-4363
    投资者关系部总监
    [email protected]

    Somanetics
    Bill Iacona, 248-244-1423
    首席财务官


     

     

    Covidien Announces Definitive Agreement to Acquire Somanetics Corporation
    • Expands monitoring platform with market-leading technology
    • Complements existing sales infrastructure; geographic expansion opportunities
    • Strong portfolio of clinical research

    DUBLIN & TROY, Mich., Jun 16, 2010 (BUSINESS WIRE) --Covidien plc (NYSE: COV) and Somanetics Corporation (NASDAQ: SMTS) today announced that they have signed a definitive merger agreement under which Covidien will acquire all of the outstanding shares of Somanetics Corporation for $25.00 per share in cash, for a total of $250 million, net of cash acquired. This acquisition is consistent with the Covidien strategy to expand into adjacencies and invest in product categories where it can develop a global competitive advantage.

    Somanetics is a leader in cerebral and somatic oximetry. The company had sales of $50 million in 2009 and has approximately 150 employees. Its INVOS(R) (In-Vivo Optical Spectroscopy) Cerebral/Somatic Oximeter, a noninvasive patient monitor, continuously measures blood oxygen levels in the brain and in the body of patients who are at risk for restricted blood flow so clinicians can detect and correct a variety of threatening complications. The INVOS System is the only commercially-available cerebral/somatic oximeter shown to improve patient outcomes.

    "The acquisition of Somanetics will allow Covidien to broaden our product offerings and add another market-leading monitoring technology to its portfolio," said Pete Wehrly, President, Respiratory & Monitoring Solutions, Covidien. "The Somanetics product line, which we currently distribute in Europe, will expand our presence in the operating room. The acquisition will help us achieve our mission of enhancing the quality of life and improving patient outcomes."

    "We are excited about joining Covidien and enabling Somanetics' shareholders to realize enhanced value for their investment," said Bruce Barrett, President and Chief Executive Officer, Somanetics. "We have enjoyed a strong, long-standing relationship with Covidien as the exclusive European distribution partner of our INVOS System. Our proprietary technology ideally complements Covidien's portfolio of respiratory and monitoring products."

    Financial Highlights

    Under the terms of the agreement, Covidien will pay $25.00 in cash per Somanetics share for a total of approximately $250 million, net of cash acquired. The combination with Somanetics will broaden Covidien's product offerings and is expected to be accretive to both revenue and earnings growth rates over time.

    The transaction, which will take the form of an all-cash tender offer by a wholly-owned subsidiary of Covidien, followed by a second-step merger, is subject to customary closing conditions, including receipt of certain regulatory approvals, and is expected to be completed by July 31, 2010. The Boards of Directors of both companies have unanimously approved the transaction. All of the directors and executive officers of Somanetics have confirmed their intention to tender all shares held by them into the offer. Once the transaction has been completed, Covidien will report the Somanetics business as part of its Oximetry and Monitoring product line in the Medical Devices business segment.

    Assuming a closing on July 31, 2010, Covidien expects that this transaction will be dilutive to 2010 and 2011 GAAP earnings per share. On a Non-GAAP basis, excluding transaction, restructuring and other costs, the transaction is expected to be neutral to earnings per share in fiscal 2010 and slightly accretive to fiscal 2011 earnings per share.

    About Covidien

    Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2009 revenue of $10.7 billion, Covidien has 42,000 employees worldwide in more than 60 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

    About Somanetics

    Somanetics Corporation develops, manufactures and markets the INVOS(R) Cerebral/Somatic Oximeter. The INVOS System is the only commercially-available cerebral/somatic oximeter with labeling for improved outcomes after surgery in patients above 2.5 kg. The INVOS System is the clinical reference standard in cerebral/somatic oximetry, with a 12-year market track record, more than 750 clinical references and implementation at approximately 800 U.S. hospitals. Somanetics also develops, manufactures and markets the Vital Sync(TM) System, a device that integrates data from bedside devices into a single system for enhanced patient assessment and decision making, data management and data storage. Somanetics supports its customers through a direct U.S. sales force and clinical education team. Covidien markets INVOS System products in Europe, Canada, the Middle East and South Africa and Edwards Lifesciences represents INVOS System products in Japan. For more information, visit //www.somanetics.com/.

    FORWARD-LOOKING STATEMENTS

    This release contains forward-looking statements that are not historical facts.Covidien and Somanetics have identified some of these forward-looking statements with words like "believe," "may," "could," "would," "might," "possible," "will," "should," "expect," "intend," "plan," "anticipate," or "continue," the negative of these words, other terms of similar meaning or the use of future dates.Forward-looking statements in this release include without limitation statements regarding the expected timing of the completion of the transaction and statements regarding the effect of the transaction on Covidien's business and competitive position, statements regarding future innovation and market growth and statements regarding Covidien's future financial performance and financial condition. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements.Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties.Risks and uncertainties that could cause results to differ from expectations include: uncertainties as to the timing of the transaction; uncertainties as to how many of Somanetics' stockholders will tender their shares in the offer; the risk that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the effects of disruption from the transaction making it more difficult to maintain relationships with employees, customers, vendors and other business partners; the risk that stockholder litigation in connection with the transaction may result in significant costs of defense, indemnification and liability; other business effects, including the effects of industry, economic or political conditions outside of Covidien's and Somanetics' control; transaction costs; actual or contingent liabilities; and other risks and uncertainties discussed in Covidien's and Somanetics' filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections of Covidien's and Somanetics' most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, as well as the tender offer documents to be filed by Covidien DE Corp., a wholly-owned subsidiary of Covidien, and the Solicitation/Recommendation Statement to be filed by Somanetics.Neither Covidien nor Somanetics undertakes any obligation to update any forward-looking statements as a result of new information, future developments or otherwise, except as expressly required by law.All forward-looking statements in this announcement are qualified in their entirety by this cautionary statement.

    NON-GAAP Financial Information

    This release contains a non-GAAP financial measure. This non-GAAP financial measure, which is used as a measure of Covidien's performance, should be considered in addition to, not as a substitute for, or superior to, measures of Covidien's financial performance prepared in accordance with GAAP. Covidien's non-GAAP measures may be defined differently than similar terms used by other companies, and accordingly, care should be exercised in understanding how Covidien defines its non-GAAP financial measures.

    Specifically, any one-time charges for transaction, restructuring and other costs are excluded from the projected earnings per share dilution.

    Covidien management uses this non-GAAP financial measure because it believes it is useful and more meaningful to assess projected earnings per share dilution excluding the transaction-related expenses. This non-GAAP financial measure is also used by Covidien's management in its financial and operating decision-making because management believes it reflects the underlying economics of Covidien's ongoing business in a manner that allows meaningful period-to-period comparisons. Such comparisons may be more meaningful because operating results presented under GAAP may include, from time to time, items that are not necessarily relevant to understand Covidien's business and may, in some cases, be difficult to forecast accurately for future periods. Covidien's management believes that this non-GAAP financial measure provides useful information to investors and others in understanding and evaluating Covidien's current operating performance and future prospects in the same manner as management does if they so choose. Non-GAAP financial measures have limitations, however, because they do not include all items of income and expense that affect Covidien's operations. Covidien's management compensates for this and other limitations by also considering Covidien's financial results as determined in accordance with GAAP.

    IMPORTANT INFORMATION ABOUT THE TENDER OFFER

    This release is neither an offer to purchase nor a solicitation of an offer to sell any securities of Somanetics Corporation. Covidien DE Corp.("Purchaser"), an indirect, wholly-owned subsidiary of Covidien, has not commenced the tender offer for the shares of Somanetics common stock described in this release.

    Upon commencement of the tender offer, Purchaser will file with the SEC a tender offer statement on Schedule TO and related exhibits, including the offer to purchase, letter of transmittal, and other related documents. Following commencement of the tender offer, Somanetics will file with the SEC a tender offer solicitation/recommendation statement on Schedule 14D-9. These documents will contain important information about Covidien, Somanetics, the transaction and other related matters. Investors and security holders are urged to read each of these documents carefully when they are available.

    Investors and security holders will be able to obtain free copies of the tender offer statement, the tender offer solicitation/recommendation statement and other documents filed with the SEC by Purchaser and Somanetics through the web site maintained by the SEC at www.sec.gov. In addition, investors and security holders will be able to obtain free copies of these documents by contacting:

    Covidien
    Investor Relations
    508-452-4650
    [email protected]

    or

    Somanetics Corporation
    Investor Relations
    248-244-1409
    [email protected]

    SOURCE: Covidien

    Covidien
    Eric Kraus, 508-261-8305
    Senior Vice President
    Corporate Communications
    [email protected]
    or
    Coleman Lannum, CFA, 508-452-4343
    Vice President
    Investor Relations
    [email protected]
    or
    Bruce Farmer, 508-452-4372
    Vice President
    Public Relations
    [email protected]
    or
    Brian Nameth, 508-452-4363
    Director
    Investor Relations
    [email protected]
    or
    Somanetics
    Bill Iacona, 248-244-1423
    Chief Financial Officer
    (来源: Covidien )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, 时时彩网络平台,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 福彩3d三注精选 江苏体彩e球彩 口袋棋牌锐游三张牌 11选五选号技巧 广东36选7好彩3 天霁彩票论坛 北京11选5新玩法 管家婆六合图库www 浙江快乐12遗漏 六合彩结果 彩票合买 上海快3秒胶 北京快乐8是国家开的吗 吉林11选5奖金规则 nba篮球排行榜